-
1
-
-
0028127412
-
Therapeutic-class wars - Drug promotion in a competitive marketplace
-
DOI 10.1056/NEJM199411173312007
-
Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars: drug promotion in a competitive marketplace. N Engl J Med. 1994;331(20): 1350-1353. (Pubitemid 24347007)
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.20
, pp. 1350-1353
-
-
Kessler, D.A.1
Rose, J.L.2
Temple, R.J.3
Schapiro, R.4
Griffin, J.P.5
-
2
-
-
49849101435
-
The ADVANTAGE seeding trial: A review of internal documents
-
Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008;149(4):251-258.
-
(2008)
Ann Intern Med
, vol.149
, Issue.4
, pp. 251-258
-
-
Hill, K.P.1
Ross, J.S.2
Egilman, D.S.3
Krumholz, H.M.4
-
4
-
-
33747085562
-
Narrative review: The promotion of gabapentin: An analysis of internal industry documents
-
Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4):284-293. (Pubitemid 46768613)
-
(2006)
Annals of Internal Medicine
, vol.145
, Issue.4
, pp. 284-293
-
-
Steinman, M.A.1
Bero, L.A.2
Chren, M.-M.3
Landefeld, C.S.4
-
7
-
-
33744997470
-
Every document and picture tells a story: Using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising
-
DOI 10.1136/tc.2005.013854
-
Anderson SJ, Dewhirst T, Ling PM. Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising. Tob Control. 2006;15(3):254-261. (Pubitemid 43864882)
-
(2006)
Tobacco Control
, vol.15
, Issue.3
, pp. 254-261
-
-
Anderson, S.J.1
Dewhirst, T.2
Ling, P.M.3
-
8
-
-
0003012924
-
How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93
-
Wayne GF, Connolly GN. How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93. Tob Control. 2002;11(suppl 1):I32-I39.
-
(2002)
Tob Control
, vol.11
, Issue.SUPPL. 1
-
-
Wayne, G.F.1
Connolly, G.N.2
-
9
-
-
42249098105
-
Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation
-
DOI 10.1001/jama.299.15.1800
-
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299(15):1800-1812. (Pubitemid 351549971)
-
(2008)
JAMA - Journal of the American Medical Association
, vol.299
, Issue.15
, pp. 1800-1812
-
-
Ross, J.S.1
Hill, K.P.2
Egilman, D.S.3
Krumholz, H.M.4
-
10
-
-
79960111418
-
Fax from Andrea Rose to Dr. XXXXX: Informed consent form and clinical study agreement for Neurontin STEPS study
-
March 30, Bates Nos. WLC/CBU 137698-137710 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Fax from Andrea Rose to Dr. XXXXX: Informed consent form and clinical study agreement for Neurontin STEPS study. March 30, 1995. Bates Nos. WLC/CBU 137698-137710. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU -137698.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
12
-
-
0033010132
-
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study
-
DOI 10.1111/j.1528-1157.1999.tb00804.x
-
McLean MJ, Morrell MJ, Willmore LJ, et al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia. 1999;40(7):965-972. (Pubitemid 29316052)
-
(1999)
Epilepsia
, vol.40
, Issue.7
, pp. 965-972
-
-
McLean, M.J.1
Morrell, M.J.2
Willmore, L.J.3
Privitera, M.D.4
Faught, R.E.5
Holmes, G.L.6
Magnus-Miller, L.7
Bernstein, P.8
Rose-Legatt, A.9
-
13
-
-
0033918752
-
Efficacy of gabapentin as adjunctive therapy in a large, multicenter study
-
DOI 10.1053/seiz.2000.0407
-
Morrell MJ, McLean MJ, Willmore LJ, et al; STEPS Study Group. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. Seizure. 2000; 9(4):241-248. (Pubitemid 30427131)
-
(2000)
Seizure
, vol.9
, Issue.4
, pp. 241-248
-
-
Morrell, M.J.1
McLean, M.J.2
Willmore, L.J.3
Privitera, M.D.4
Faught, R.E.5
Holmes, G.L.6
Magnus, L.7
Bernstein, P.8
Rose-Legatt, A.9
-
14
-
-
79960146469
-
Letter from Peter Kaplan to Andrea Rose re: STEPS IRB approval
-
May 1, Bates Nos. Pfizer/TMF/CRF 0046561-45568. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Peter Kaplan to Andrea Rose re: STEPS IRB approval. May 1, 1995. Bates Nos. Pfizer/TMF/CRF 0046561-45568. http://www.egilman.com/neurontindocs/ STEPS %20Docs/PFIZER-TMF-CRF-046561.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
15
-
-
79960119863
-
Parke- Davis record of FDA contact by Irwin Martin
-
November 30, Bates Nos. WLC/CBU 119162-119168. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis record of FDA contact by Irwin Martin. November 30, 1994. Bates Nos. WLC/CBU 119162-119168. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-119162.pdf. Accessed December 26, 2010.
-
(1994)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
16
-
-
79960144819
-
Parke- Davis memo from Patrick Reichenberger to John McCarthy re: Neurontin activities
-
April 11, Bates Nos. WLC/CBU 035854-035855. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Patrick Reichenberger to John McCarthy re: Neurontin activities. April 11, 1997. Bates Nos. WLC/CBU 035854-035855. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-035854.pdf. Accessed December 26, 2010.
-
(1997)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
17
-
-
79960121809
-
Letter from Barbara Rainville to Andrea Rose-Legat re: Data clean-up process
-
April 17, Bates Nos. Pfizer/TMF/CRF 0046087-0046093. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Barbara Rainville to Andrea Rose-Legat re: data clean-up process. April 17, 1996. Bates Nos. Pfizer/TMF/CRF 0046087-0046093. http://www.egilman. com /neurontindocs/STEPS%20Docs/PFIZER-TMF-CRF-046087.pdf. Accessed December 26, 2010.
-
(1996)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
18
-
-
79960132629
-
Letter from Jo-Anne Paul to Paula Podolnick re: STEPS: seizure frequency assessment visits
-
January 20, Bates Nos. Pfizer/TMF/CRF 047477-047478. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Letter from Jo-Anne Paul to Paula Podolnick re: STEPS: seizure frequency assessment visits. January 20, 1997. Bates Nos. Pfizer/TMF/CRF 047477-047478. http://www.egilman.com/neurontindocs/STEPS%20Docs/PFIZER-TMF-CRF-047477.pdf. Accessed December 26, 2010.
-
(1997)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
19
-
-
79960123770
-
Parke- Davis Memo from Laura Johnson to area business managers re: Northeast Anticonvulsant Advisory Board Meeting
-
January 4, Bates Nos. WLC/CBU 156787-156788. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo from Laura Johnson to area business managers re: Northeast Anticonvulsant Advisory Board Meeting. January 4, 1996. Bates Nos. WLC/CBU 156787-156788. http://www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-156787. pdf. Accessed December 26, 2010.
-
(1996)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
20
-
-
79960128286
-
Parke- Davis marketing report re 1995 Neurontin situation analysis
-
September 20, Bates Nos. WLC/CBU 094876-094883 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis marketing report re 1995 Neurontin situation analysis. September 20, 1995. Bates Nos. WLC/CBU 094876-094883. http://www.egilman.com/ neurontindocs/STEPS%20Docs/WLC-CBU-094876.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
21
-
-
79960136046
-
Parke- Davis memo re: Revised North Central CBU Neurontin "Plus" Plan
-
April 19, Bates Nos. WLC/CBU 136177-136190. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo re: revised North Central CBU Neurontin "Plus" Plan. April 19, 1995. Bates Nos. WLC/CBU 136177-136190. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-136177.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
22
-
-
79960115426
-
Parke-Davis memo from Tom Gorda to the NECBU re: Neurontin "Plus" Plans
-
June 2, Bates Nos. WLC/CBU 153605-153606. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke-Davis memo from Tom Gorda to the NECBU re: Neurontin "Plus" Plans. June 2, 1995. Bates Nos. WLC/CBU 153605-153606. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-153605.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
23
-
-
79960110963
-
Parke- Davis Memo re: Neurontin STEPS videoconference
-
December 30, Bates Number WLC/CBU 146788 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo re: Neurontin STEPS videoconference. December 30, 1994. Bates Number WLC/CBU 146788. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-146778.pdf. Accessed December 26, 2010.
-
(1994)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
24
-
-
79960117864
-
Parke- Davis Powerpoint re: CNS Marketing Task Force Briefing
-
March 30, Bates Nos. WLC/CBU 084368-84401. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Powerpoint re: CNS Marketing Task Force Briefing. March 30, 1995. Bates Nos. WLC/CBU 084368-84401. http://www.egilman.com/neurontindocs/STEPS %20Docs/WLC-CBU-084368.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
25
-
-
79960146967
-
Parke- Davis meeting minutes on Neurontin Development Team Meeting
-
March 16, Bates Nos. WLC/CBU 170739-170744. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis meeting minutes on Neurontin Development Team Meeting. March 16, 1995. Bates Nos. WLC/CBU 170739-170744. http://www.egilman.com/neurontindocs /STEPS%20Docs/WLC-CBU-170739.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
26
-
-
79960143502
-
Parke- Davis collected materials on Introductory Investigators briefing
-
March 4, Bates Nos. WLC/CBU 036290-036376 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis collected materials on Introductory Investigators briefing. March 4, 1995. Bates Nos. WLC/CBU 036290-036376. http://www.egilman.com/neurontindocs /STEPS%20Docs/WLC-CBU-036290.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
27
-
-
79960145207
-
Parke- Davis Memo from David Davis to Rick Bancharsky re: STEPS hospital sites
-
January 26, Bates Nos. WLC/CBU 153844-153846 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis Memo from David Davis to Rick Bancharsky re: STEPS hospital sites. January 26, 1995. Bates Nos. WLC/CBU 153844-153846. http://www.egilman.com /neurontindocs/STEPS%20Docs/WLC-CBU-153844.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
28
-
-
79960142047
-
Parke- Davis memo from Andrea Rose to Parke-Davis distribution list re: Neurontin STEPS study enrollment
-
June 28, Bates Nos. WLC/CBU 153523-153524 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Andrea Rose to Parke-Davis distribution list re: Neurontin STEPS study enrollment. June 28, 1995. Bates Nos. WLC/CBU 153523-153524. http: //www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU- 153523.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
29
-
-
79960149616
-
Parke- Davis memo from Rich Weiss to Mike Hoffman et al re: Neurontin CONTROL study
-
December 5, Bates No. WLC/Franklin 00000039903 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Rich Weiss to Mike Hoffman et al re: Neurontin CONTROL study. December 5, 1994. Bates No. WLC/Franklin 00000039903. http://www.egilman .com/neurontindocs/STEPS%20Docs/WLC-FRANKLIN-0000039903.pdf. Accessed December 26, 2010.
-
(1994)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
30
-
-
79960143921
-
Parke- Davis memo from Epilepsy Marketing Team to distribution list re: Situation analysis for Neurontin
-
June 12, Bates Nos. WLC/CBU 090238-090256. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Epilepsy Marketing Team to distribution list re: situation analysis for Neurontin. June 12, 1996. Bates Nos. WLC/CBU 090238-090256. http: //www.egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU- 090238.pdf. Accessed December 26, 2010.
-
(1996)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
31
-
-
79960129590
-
Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: Selected physician titration analysis
-
July 26, Bates Nos. WLC/CBU 089640-089643. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: selected physician titration analysis. July 26, 1995. Bates Nos. WLC/CBU 089640-089643. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-089640.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
32
-
-
79960129590
-
Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: Selected physician titration analysis
-
November 9, Bates Nos. WLC/CBU 089593-089595 Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Jan Rizzo to Lara Ulrich et al re: selected physician titration analysis. November 9, 1995. Bates Nos. WLC/CBU 089593-089595. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-CBU-089593.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
33
-
-
79960123146
-
Parke- Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports
-
October 23, Bates Nos. WLC/Franklin 000033263-0000033271. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke- Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports. October 23, 1995. Bates Nos. WLC/Franklin 000033263-0000033271. http://www .egilman.com/neurontindocs/STEPS%20Docs/WLC-FRANKLIN-0000033263 .pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
34
-
-
79960123146
-
Parke-Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports
-
December 7, Bates Nos.WLC/CBU146230-146239. Accessed December 26, 2010
-
Neurontin Marketing, Sales Practices, and Product Liability Litigation. Parke-Davis memo from Lawton Griffin to Edda Guerrero re: AED monthly reports. December 7, 1995. Bates Nos.WLC/CBU146230-146239. http://www.egilman.com/ neurontindocs /STEPS%20Docs/WLC-CBU-146230.pdf. Accessed December 26, 2010.
-
(1995)
Neurontin Marketing, Sales Practices, and Product Liability Litigation
-
-
-
35
-
-
33745235139
-
How conducting a clinical trial affects physicians' guideline adherence and drug preferences
-
Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006;295(23): 2759-2764.
-
(2006)
JAMA
, vol.295
, Issue.23
, pp. 2759-2764
-
-
Andersen, M.1
Kragstrup, J.2
Søndergaard, J.3
-
36
-
-
0004177252
-
-
Web site. Accessed December 26, 2010
-
Declaration of Helsinki. http://www.wma.net/en/30publications/10policies/ b3 /index.html. World Medical Association Web site. Accessed December 26, 2010.
-
Declaration of Helsinki
-
-
-
37
-
-
41149152920
-
Protection of human subjects
-
Accessed December 26, 2010
-
Protection of human subjects. Code of Federal Regulations. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Accessed December 26, 2010.
-
Code of Federal Regulations
-
-
-
41
-
-
4143062563
-
Oversight of human participants research: Identifying problems to evaluate reform proposals
-
Emanuel EJ, Wood A, Fleischman A, et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann Intern Med. 2004; 141(4):282-291. (Pubitemid 39089129)
-
(2004)
Annals of Internal Medicine
, vol.141
, Issue.4
, pp. 282-291
-
-
Emanuel, E.J.1
Wood, A.2
Fleischman, A.3
Bowen, A.4
Getz, K.A.5
Grady, C.6
Levine, C.7
Hammerschmidt, D.E.8
Faden, R.9
Eckenwiler, L.10
Muse, C.T.11
Sugarman, J.12
|